Abstract:Abstract Background: B-cell activating factor (BAFF) is vital for B cell survival. Serum BAFF levels are elevated in thrombotic antiphospholipid syndrome, but little is known about levels in patients with positive antiphospholipid antibodies (aPLs) and previous adverse pregnancy outcomes (APOs). We aimed to analyze serum BAFF concentrations of these patients in early pregnancy along with different pregnancy outcomes. Methods: Thirty-six pregnant patients positive for aPLs and previous APOs (patient group), 25 healthy pregnant females (HP group) and 35 healthy non-pregnant females (HNP group) from the Peking University Third Hospital, between October 2018 and March 2019, were enrolled in this study. Serum of HNP and serum of patients as well as HP in the first gestational trimester were collected. Enzyme-linked immunosorbent assay kits were used to measure serum BAFF and interferon-alpha (IFN-α) concentrations. Cytometric bead array analysis was used to measure serum concentrations of cytokines. The patient group was further divided into APOs and non-APOs (NAPOs) group, fetal loss and live birth group according to pregnancy outcomes. The Mann-Whitney U-test was used to assess significance between and within groups. Spearman rank-order was used to evaluate correlation coefficients between BAFF and related cytokines. Results: The serum BAFF level in HP group was significantly lower than HNP group (245.24 [218.80, 265.90] vs. 326.94 [267.31, 414.80] pg/mL, Z = −3.966, P < 0.001). The BAFF level was obviously elevated in patient group compared to that in HP group (307.77 [219.86, 415.65] vs. 245.24 [218.80, 265.90] pg/mL, Z = −2.464, P = 0.013). BAFF levels in APOs group tended to be higher than that in NAPOs group (416.52 [307.07, 511.12] vs. 259.37 [203.59, 375.81] pg/mL, Z = −2.718, P = 0.006). Compared to HP group, concentrations of IFN-α, interleukin (IL-6) and tumor necrosis factor were higher in patient group (33.37 [18.85, 48.12] vs. 13.10 [6.85, 25.47] pg/mL, Z = −2.023, P = 0.043; 39.16 [4.41, 195.87] vs. 3.37 [2.92, 3.90] pg/mL, Z = −3.650, P < 0.001; 8.23 [2.27, 64.46] vs. 1.53 [1.25, 2.31] pg/mL, Z = −3.604, P < 0.001, respectively). Serum BAFF levels had a positive correlation with the concentrations of both IL-6 and IL-10 (IL-6: r = 0.525, P = 0.002; IL-10: r = 0.438, P = 0.012). Conclusions: Serum BAFF levels are increased in patients with positive aPLs and previous APOs as compared to healthy pregnant females and tend to be higher in individuals with current APOs. The BAFF levels have a positive correlation with serum IL-6 and IL-10.

Serum BAFF and APRIL Levels in Patients with Autoimmune Hemolytic Anemia and Their Clinical Significance.

Baff Level Increased in Patients with Autoimmune Hemolytic Anemia

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Serum BAFF and APRIL Might Be Associated with Disease Activity and Kidney Damage in Patients with Anti‐glomerular Basement Membrane Disease

Functions of B-cell-activating factor in autoimmune diseases

Detection of regulary B cell subsets and IL-10,TGF-β1 in peripheral blood of autoimmune haemolytic anaemia patients

Change of Serum B-cell Activating Factor Level in Patients with Positive Antiphospholipid Antibodies and Previous Adverse Pregnancy Outcomes and Its Significance

High APRIL Levels Are Associated With Slow Disease Progression and Low Immune Activation in Chronic HIV-1-Infected Patients

The Role of T Follicular Helper Cells and T Follicular Regulatory Cells in the Pathogenesis of Autoimmune Hemolytic Anemia

Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: Correlation with clinical features and Streptococcus pyogenes infection

IL-33 Reflects Dynamics of Disease Activity in Patients with Autoimmune Hemolytic Anemia by Regulating Autoantibody Production

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy

B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation

Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy

Serum BAFF level is associated with the presence and severity of coronary artery disease and acute myocardial infarction

Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.

Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia

Serum B-Cell Activating Factor in Myecloperoxiase-Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis

BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis

Correlation of Serum B Cell Activating Factor with Disease Activity in Patients with Systemic Lupus Erythematosus